Login Register Cart 0
Generic placeholder image

Recent Advances in Drug Delivery and Formulation

Editor-in-Chief

ISSN (Print): 2667-3878
ISSN (Online): 2667-3886

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Research Article

Development of Niosomal Vesicles Loaded Mometasone Furoate Gel for Transdermal Delivery and its Evaluation

Author(s): Bhushan R. Rane*, Pushkar Y. Chavan, Nidhi S. Kate and Ashish S. Jain

Volume 17, Issue 4, 2023

Published on: 16 November, 2023

Page: [300 - 313] Pages: 14

DOI: 10.2174/0126673878259437231031114907

Price: $65

Abstract

Background: Mometasone Furoate (MF) is a corticosteroid (glucocorticoid) used to treat eczema, psoriasis, allergies, and rash on the skin; also used to reduce itching, redness, and swelling (inflammation). It has been reported that the bioavailability of MF is less than 11% when given via the nasal route. Encapsulating the drug in niosomes can improve the active pharmaceutical ingredient's bioavailability by enhancing both physical and biological stability.

Objective: The goal of the study is to develop, a non-ionic surfactant-based vesicular system, by loading mometasone furoate, and introducing it into a gel-based formulation by utilizing an appropriate gelling agent, and performing its evaluation.

Methods: The niosome vesicle was prepared by vacuum rotary evaporation method (Thin film hydration method). Gel was prepared using the dispersion method and in-vitro drug diffusion studies using Franz-diffusion cells.

Results: According to the results of the experiments conducted for the study, Mometasone Furoate niosomal gel was prepared utilizing Mometasone Furoate niosomes that were made using the thin film hydration process, Cholesterol, and Span 60, and loaded in various amounts of Carbopol as a geling agent. The niosomes' zeta potential was found to be -24 mV, showing that the formulation is stable. The polydispersity index (PDI) was found to be 0.409 and the average size of niosomes to be 252.7 nm. The performance of the gel of the optimized formulations containing 2% Carbopol showed in vitro diffusion for 7 hours and an increased flux rate as compared to the plain MF.

Conclusion: The experiments carried out during the study led to the conclusion that the thin-film hydration method was suitable for the formation of the MF-niosomes by using Span 60 and Cholesterol (2:1). The gel formulation containing 2% Carbopol indicated better in vitro diffusion following the Higuchi model across all niosomal gel formulations. Niosomal gel can be regarded as the best vesicular carrier for the efficient distribution of mometasone furoate via the transdermal route.

« Previous Next »
Graphical Abstract

[1]
Nerkar AG. Editorial. Curr Trends Pharma Pharmaceut Chem 2021; 3(3): 1-2.
[http://dx.doi.org/10.18231/j.ctppc.2021.001]
[2]
William B. A review on niosomes in ocular drug delivery system. Int J Res Rev 2020; 7: 484-93.
[3]
Bakliwal SR, Rane BR, Jain AS. Niosomes and Proniosomes.In:A glimpse of novel vesicular drug delivery system. Nirali Prakashan 2017.
[4]
Madhav NVS. Niosomes: A completely unique drug delivery system IJRPC 2011; 498-9.
[5]
Kauslya A, Borawake PD, Shinde JV, Chavan RS. Niosomes: A novel carrier drug delivery system. J Drug Deliv Ther 2021; 11(1): 162-70.
[http://dx.doi.org/10.22270/jddt.v11i1.4479]
[6]
Rao NN, Chowdary PSBAD, Divya Y, Laksmi TS, Latha KSS, Sirisha P. Niosomes: A vesicular drug delivery system. Res J Pharma Technol 2018; 11(8): 3731.
[http://dx.doi.org/10.5958/0974-360X.2018.00684.4]
[7]
Md U, Ghuge PR, Jain BV. Niosomes: A novel trend of drug delivery Europ J Biomed Pharm Sci 2017; 436-42.
[8]
Milan A, Mioc A, Prodea A, et al. The optimized delivery of triterpenes by liposomal nanoformulations: overcoming the challenges. Int J Mol Sci 2022; 23(3): 1140.
[http://dx.doi.org/10.3390/ijms23031140] [PMID: 35163063]
[9]
Ge X, Wei M, He S, Yuan WE. Advances of non-ionic surfactant vesicles (niosomes) and their application in drug delivery. Pharmaceutics 2019; 11(2): 55.
[http://dx.doi.org/10.3390/pharmaceutics11020055] [PMID: 30700021]
[10]
Patel HM, Patel UB. A review on niosomes - A novel approach for drug targeting Int J Adv Pharm 2020; 8.
[11]
John G, Sinha P, Rathnam G, Ubaidulla U, Aravind R. A review on future prospects of niosomes towards drug delivery applications. IOSR J Pharm 2021; 11: 1-09.
[12]
Gandhi M, Paralkar S, Sonule M, Dabhade D, Pagar S. Niosomes: Novel drug delivery system. Int J Pure Appl Biosci 2014; 2: 267-74.
[13]
Jothy M. An overview on niosome as carrier in dermal drug delivery. J Pharm Sci Res 2015; 7: 923-7.
[14]
Kumavat S, Sharma PK, Koka SS, Sharma R, Gupta A, Darwhekar GN. A review on niosomes: Potential vesicular drug delivery system. J Drug Deliv Ther 2021; 11(5): 208-12.
[http://dx.doi.org/10.22270/jddt.v11i5.5046]
[15]
Shirsand SB, Keshavshetti GG. Recent advances in niosomal drug delivery - A review Life Sci Inform 2019; 514-31.
[16]
Nasir A, Harikumar Kaur A. Niosomes: An excellent tool for drug delivery. Int J Res Pharm Chem 2012; 2.
[17]
Moghtaderi M, Sedaghatnia K, Bourbour M, et al. Niosomes: A novel targeted drug delivery system for cancer. Med Oncol 2022; 39(12): 240.
[http://dx.doi.org/10.1007/s12032-022-01836-3]
[18]
Umbarkar MG. Niosome as a novel pharmaceutical drug delivery: A brief review highlighting formulation, types, composition and application. Indian J Pharmaceut Edu Res 2021; 55(1s): s11-28.
[http://dx.doi.org/10.5530/ijper.55.1s.34]
[19]
Kamlesh Maurya , Arpita Singh , Swarnima Pandey , Nitish Kumar , Siddhiqui MA. Niosomes: Classification, preparation and application. Int J Indigenous Herbs Drugs 2021; 29–32: 29-32.
[http://dx.doi.org/10.46956/ijihd.vi.120]
[20]
Abdelkader H, Alani AWG, Alany RG. Recent advances in non-ionic surfactant vesicles (niosomes): Self-assembly, fabrication, characterization, drug delivery applications and limitations. Drug Deliv 2014; 21(2): 87-100.
[http://dx.doi.org/10.3109/10717544.2013.838077] [PMID: 24156390]
[21]
Sanklecha V M, Pande V V, Pawar S S, Pagar O B, Jadhav A C. Review on niosomes. Austin Pharmacol Pharm 2018; 3(2)
[22]
Gharbavi M, Amani J, Kheiri-Manjili H, Danafar H, Sharafi A. Niosome: A promising nanocarrier for natural drug delivery through blood-brain barrier. Adv Pharmacol Sci 2018; 2018: 1-15.
[http://dx.doi.org/10.1155/2018/6847971] [PMID: 30651728]
[23]
Abdo JM, Sopko NA, Milner SM. The applied anatomy of human skin: A model for regeneration. Wound Med 2020; 28(100179): 100179.
[http://dx.doi.org/10.1016/j.wndm.2020.100179]
[24]
G DB P VL. Recent advances of non-ionic surfactant-based nano-vesicles (niosomes and proniosomes): A brief review of these in enhancing transdermal delivery of drug. Future J Pharmaceut Sci 2020; 6(1): 100.
[http://dx.doi.org/10.1186/s43094-020-00117-y]
[25]
Kumar L, Verma S, Kumar S, Prasad DN, Jain AK. Fatty acid vesicles acting as expanding horizon for transdermal delivery. Artif Cells Nanomed Biotechnol 2017; 45(2): 251-60.
[http://dx.doi.org/10.3109/21691401.2016.1146729] [PMID: 26890090]
[26]
Ng KW, Lau WM. Skin Deep: The basics of human skin structure and drug penetration.In:Percutaneous Penetration Enhancers Chemical Methods in Penetration Enhancement. Berlin, Heidelberg, Berlin, Heidelberg: Springer 2015.
[http://dx.doi.org/10.1007/978-3-662-45013-0_1]
[27]
Srivastava NS, Thakur S, Kaur J. Niosomes: A novel approach for topical delivery of drugs. IJPT 2016; 8: 11712-31.
[28]
Momekova DB, Gugleva VE, Petrov PD. Nanoarchitectonics of multifunctional niosomes for advanced drug delivery. ACS Omega 2021; 6(49): 33265-73.
[http://dx.doi.org/10.1021/acsomega.1c05083] [PMID: 34926878]
[29]
Hamishehkar H, Rahimpour Y, Kouhsoltani M. Niosomes as a propitious carrier for topical drug delivery. Expert Opin Drug Deliv 2013; 10(2): 261-72.
[http://dx.doi.org/10.1517/17425247.2013.746310] [PMID: 23252629]
[30]
PubChem Mometasone furoate Available from: https://pubchem. ncbi.nlm.nih.gov/compound/Mometasone-furoate (accessed 2022-10-13)
[31]
Lyseng-Williamson KA. Mometasone furoate 0.1% ointment and hydrogel: A guide to their use in corticosteroid-responsive dermatoses. Drugs Ther Perspect 2016; 32(10): 407-13.
[http://dx.doi.org/10.1007/s40267-016-0339-9]
[32]
Tarekegn A, Joseph N, Palani S. Niosomes in targeted drug delivery: Some recent advances. Int J Pharm Sci Res 2010; 1(9)
[33]
Thabet Y, Elsabahy M, Eissa NG. Methods for preparation of niosomes: A focus on thin-film hydration method. Methods 2022; 199: 9-15.
[http://dx.doi.org/10.1016/j.ymeth.2021.05.004] [PMID: 34000392]
[34]
Akbarzadeh I, Sedaghatnia K, Bourbour M, et al. Niosomes: A novel targeted drug delivery system. Preprints 2021; 2021; 202112.
[http://dx.doi.org/10.20944/preprints202112.0315.v1]
[35]
Bharath MS, Rane BR, Jain AS. Formulation development and evaluation of transfero-somes nano gel loaded with levocetirizine transfero-somes. Int J Pharmaceutl Scil Nanotechnol 2021; 14(2): 5383-95. [IJPSN]
[http://dx.doi.org/10.37285/ijpsn.2021.14.2.4]
[36]
Rane BR, Patil RS, Jain AS. Formulation development and evaluation of nanogel loaded with montelukast sodium niosomes. Int J Pharm Sci Res 2021; 12(8): 4208-21.
[37]
Gharib R, Greige-Gerges H, Fourmentin S, Charcosset C, Auezova L. Liposomes incorporating cyclodextrin-drug inclusion complexes: Current state of knowledge. Carbohydr Polym 2015; 129: 175-86.
[http://dx.doi.org/10.1016/j.carbpol.2015.04.048] [PMID: 26050903]
[38]
Rajera R, Nagpal K, Singh SK, Mishra DN. Niosomes: a controlled and novel drug delivery system. Biol Pharm Bull 2011; 34(7): 945-53.
[http://dx.doi.org/10.1248/bpb.34.945] [PMID: 21719996]
[39]
Jain V. Formulation development and evaluation of niosomal gel of tazarotene for treatment of psoriasis. J Med Pharmaceut All Sci 2021; 10(1): 2664-70.
[http://dx.doi.org/10.22270/jmpas.v10i1.1030]
[40]
Shilakari Asthana G, Sharma PK, Asthana A. In vitro and in vivo evaluation of niosomal formulation for controlled delivery of clarithromycin. Scientifica 2016; 2016: 1-10.
[http://dx.doi.org/10.1155/2016/6492953] [PMID: 27293976]
[41]
Fang JY, Yu SY, Wu PC, et al. In Vitro skin permeation of estradiol from various proniosome formulations. Int J Pharm 2001; 215(1-2): 91-9.
[http://dx.doi.org/10.1016/S0378-5173(00)00669-4] [PMID: 11250095]
[42]
Louis D. An overview on niosomes: A drug nanocarrier. Drug Desig Intell Prop Int J 2018; 1(5)
[http://dx.doi.org/10.32474/DDIPIJ.2018.01.000125]
[43]
Rathod JH, Mehta PD. A review on pharmaceutical gel. Int J Pharma Sci 2015; 1: 33-47.
[44]
Soni A. Review on: Novel approach in pharmaceutical gel. J Pharm Res 2019; 8(6): 429-35.
[http://dx.doi.org/10.5281/ZENODO.3265342]
[45]
B SA, Jeganath S, Jeevitha E. Pharmaceutical gels and recent trends-A review. Res J Pharma Technol 2019; 12(12): 6181.
[http://dx.doi.org/10.5958/0974-360X.2019.01073.4]
[46]
Patil P, Datir S, Saudagar R. A review on topical gels as drug delivery system. JDDT 2019; 9: 989-94.
[47]
Basha N, Prakasam B, Goli K. Formulation and evaluation of gel containing fluconazole-antifungal agent. Int J Drug Dev Res 2011; 3: 109-28.
[48]
Sharma D, Ali AAE, Aate JR. Niosomes as novel drug delivery system: Review article. Pharmatutor 2018; 6(3): 58.
[http://dx.doi.org/10.29161/PT.v6.i3.2018.58]
[49]
Raval N, Maheshwari R, Kalyane D, Youngren-Ortiz SR, Chougule MB, Tekade RK. Importance of physicochemical characterization of nanoparticles in pharmaceutical product development.In: Basic Fundamentals of Drug Delivery. Elsevier 2019; pp. 369-400.
[http://dx.doi.org/10.1016/B978-0-12-817909-3.00010-8]
[50]
Lopes SC, De A, Giuberti C, et al. Liposomes as carriers of anticancer drugs.In: Cancer Treatment. InTech 2013.
[51]
Jadon PS, Gajbhiye V, Jadon RS, Gajbhiye KR, Ganesh N. Enhanced oral bioavailability of griseofulvin via niosomes. AAPS PharmSciTech 2009; 10(4): 1186-92.
[http://dx.doi.org/10.1208/s12249-009-9325-z] [PMID: 19856107]
[52]
Jarrar QB, Hakim MN, Cheema MS, Zakaria ZA. In vitro characterization and in vivo performance of mefenamic acid-sodium diethyldithiocarbamate based liposomes. Braz J Pharm Sci 2019; 55(12): 97902019000117870.
[53]
Owodeha-Ashaka K, Ilomuanya MO, Iyire A. Evaluation of sonication on stability-indicating properties of optimized pilocarpine hydrochloride-loaded niosomes in ocular drug delivery. Prog Biomater 2021; 10(3): 207-20.
[http://dx.doi.org/10.1007/s40204-021-00164-5] [PMID: 34549376]
[54]
Abasaheb Borse V, Gangude AB, Deore AB. Formulation and evaluation of antibacterial topical gel of doxycycline hyclate, neem oil and tea tree oil. Indian J Pharmaceut Edu Res 2019; 54(1): 206-12.
[http://dx.doi.org/10.5530/ijper.54.1.24]
[55]
Alalor CA, Jokor PE. Evaluation of diclofenac niosomal gel formulated with <i>Grewia</i> gum for topical delivery. J Pharm Bioresour 2020; 17(1): 13-8.
[http://dx.doi.org/10.4314/jpb.v17i1.3]
[56]
Shirisha N, Ui F. Formulation and evaluation of mefenamic acid niosomal gel. J Pharmaceut Nanotechnol 2022.
[57]
Gupta R. Formulation development and evaluation of anti-inflammatory potential of cordia obliqua topical gel on animal model. Pharmacogn J 2017; 9(6s): s93-8.
[http://dx.doi.org/10.5530/pj.2017.6s.163]
[58]
Aiyalu R, Govindarjan A, Ramasamy A. Formulation and evaluation of topical herbal gel for the treatment of arthritis in animal model. Braz J Pharm Sci 2016; 52(3): 493-507.
[http://dx.doi.org/10.1590/s1984-82502016000300015]
[59]
Shaik F. Formulation development and evaluation of carbopol-incorporated mucoadhesive thermoreversible gels of sucralfate for rectal drug delivery. Hacettepe Univ J Faculty Pharma 2021; 41(4): 234-42.
[http://dx.doi.org/10.52794/hujpharm.1012883]
[60]
Samreen M. Formulation and in-vitro evaluation of niosomal drug delivery system for aceclofenac. Int J Res Pharmaceut Sci Technol 2019; 1: 84-8.
[http://dx.doi.org/10.33974/ijrpst.v1i3.151]
[61]
Ali J, Khan AW, Kotta S, Ansari SH, Sharma RK, Kumar A. Formulation development, optimization and evaluation of aloe vera gel for wound healing. Pharmacogn Mag 2013; 9(36): 6.
[http://dx.doi.org/10.4103/0973-1296.117849] [PMID: 24143047]
[62]
Kumar TP, Eswaraiah MC. Formulation and evaluation of topical hydrogel containing antifungal drug. Pharm Pharmacol Int J 2020; 8(4): 249-54.
[http://dx.doi.org/10.15406/ppij.2020.08.00302]
[63]
Salgado ACGB, Silva AMNN, Machado MCJC, Duarte MASC, Ribeiro HMOM. Development, stability and in vitro permeation studies of gels containing mometasone furoate for the treatment of dermatitis of the scalp. Braz J Pharm Sci 2010; 46(1): 109-14.
[http://dx.doi.org/10.1590/S1984-82502010000100012]
[64]
Neher A, Gstöttner M, Scholtz A, Nagl M. Antibacterial activity of mometasone furoate. Arch Otolaryngol Head Neck Surg 2008; 134(5): 519-21.
[http://dx.doi.org/10.1001/archotol.134.5.519] [PMID: 18490574]
[65]
Nagalakshmi S, Damodharan N, Thanka J, Seethalakshmi S. Niosomes in ocular drug delivery system: A review of magic targeted drug delivery. Int J Pharm Sci Rev Res 2015; 32: 61-6.
[66]
Bibi S, Kaur R, Henriksen-Lacey M, et al. Microscopy imaging of liposomes: From coverslips to environmental SEM. Int J Pharm 2011; 417(1-2): 138-50.
[http://dx.doi.org/10.1016/j.ijpharm.2010.12.021] [PMID: 21182914]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy